Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

被引：13

作者：

Locke, Frederick Lundry

Ghobadi, Armin

Lekakis, Lazaros J.

Miklos, David Bernard

Jacobson, Caron A.

Jacobsen, Eric D.

Braunschweig, Ira

Oluwole, Olalekan O.

Siddiqi, Tanya

Lin, Yi

Reagan, Patrick Michael

Farooq, Umar

Deol, Abhinav

Bot, Adrian

Rossi, John M.

Jiang, Yizhou

Xue, Allen

Go, William Y.

Neelapu, Sattva Swarup

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3039

引用

页数：2

共 50 条

[1] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick
Bartlett, Nancy
Jacobson, Caron
Oluwole, Olalekan
Munoz, Javier
Lekakis, Lazaros
Topp, Max
Avivi, Irit
Kim, Jenny
Chu, Rong
Zheng, Lianqing
Rossi, John
Bot, Adrian
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
[3] RESULTS BY PRIOR LOT IN ZUMA-1, PIVOTAL STUDY PHASE 1/2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Jacobsen, E.
Braunschweig, I
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Reagan, P. M.
Farooq, U.
Deol, A.
Bot, A.
Rossi, J. M.
Jiang, Y.
Xue, A.
Go, W. Y.
Neelapu, S. S.
HAEMATOLOGICA, 2018, 103 : 96 - 96
[4] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianging
Rossi, John M.
Locke, Frederick L.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
[5] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick L.
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
[6] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David Bernard
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
Locke, Frederick L.
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David B.
Jacobson, Caron A.
Jacobsen, Eric
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Reagan, Patrick M.
Farooq, Umar
Deol, Abhinav
Bot, Adrian
Rossi, John M.
Jiang, Yizhou
Xue, Allen
Go, William Y.
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S276 - S276
[8] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, F. L.
Bartlett, N. L.
Jacobson, C. A.
Oluwole, O. O.
Munoz, J.
Lekakis, L. J.
Topp, M. S.
Avivi, I
Kim, J. J.
Chu, R.
Zheng, L.
Rossi, J. M.
Bot, A.
Neelapu, S. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
[9] Outcomes by Prior Lines of Therapy in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel in Patients With Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 11 - 13
[10] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Jacobson, C. A.
Jacobsen, E.
Miklos, D. B.
Lekakis, L. J.
Braunschweig, I
Oluwole, O. O.
Lin, Y.
Siddiqi, T.
Deol, A.
Reagan, P. M.
Farooq, U.
Bot, A.
Jiang, Y.
Rossi, J. M.
Xue, A.
Go, W. Y.
Neelapu, Sattva S.
HAEMATOLOGICA, 2018, 103 : 95 - 96

← 1 2 3 4 5 →